Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines Inc - Ordinary Shares

Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. The RASolute 303 study, formally titled “A Phase 3 Global, ...

Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside Potential

In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Revolution Medicines, with a price target of $263.00. Z...

LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)

In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Revolution Medicines, with a price target of $200.00. Accordi...

Evercore ISI Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Revolution Medicines (RVMD), Penumbra (PEN) and BioCryst (BCRX). ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Penumbra (PEN) and BioCryst (BCRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbCellera Biologics (ABCL) and Revolution Medicines ...

Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL) and Revolution Medicines (RVMD)

In a report released today, Laura Prendergast from Stifel Nicolaus maintained a Buy rating on Revolution Medicines, with a price target of $215.00....

Market Cap	$11.79B	P/E Ratio	N/A
52W High	$156.25	52W Low	$34.00
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-24.5%	52W Position	98.9%
Overall Score	44	Value Score	40
Quality Score	39	Technical Score	54

EPS Current Est	$-7.75	EPS Next Est	$-4.96
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RVMD	$154.89	+2.20%	2.38M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RVMD	$154.89	+2.2%	2.38M
3
4
5
6

RVMD

RVMD

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Revolution Medicines Inc - Ordinary Shares Data in Excel

Get Revolution Medicines Inc - Ordinary Shares Data in Excel